Researcher Annalaura Mastrangelo receives the 2026 Young Investigator Award in the Basic Science category

Researcher Annalaura Mastrangelo, from the  Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), has been awarded the 2026 Young Investigator Award of the European Atherosclerosis Society (EAS) in the Basic category for her research entitled “Imidazole propionate is a driver and therapeutic target in atherosclerosis,” published in the journal Naturein 2024.

The EAS Young Investigator Awards 2026 celebrate outstanding early-career researchers for their exceptional contributions to atherosclerosis and related metabolic disorders.  Each award, valued at €2,000, recognizes groundbreaking publications that advance scientific knowledge in these fields.

Annalaura Mastrangelo is a researcher in the laboratory of Dr. David Sancho. She received her international PhD in Medicinal Chemistry from Universidad San Pablo CEU in 2017, where she developed metabolomics approaches to identify metabolic signatures associated with metabolic and inflammatory diseases in human cohorts. Her research focuses on microbiota‑derived metabolites and immunometabolic regulation in cardiovascular disease, integrating metabolomics with experimental and translational models to uncover mechanisms linking metabolism, immune activation, and atherosclerosis.

This year’s winners in both the Basic and Clinical categories will present their papers on the EAS Stage during the EAS Congress in Athens, Greece.